StockData
Innate Pharma SA logo

Innate Pharma SA (IPHA) income statement

IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$1.33−0.07 (-5.34%)

Close on Nov 17, 2026Market cap $124.65MP/E –Yield –

Innate Pharma SA income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
–
Operating margin
-599.8%
Net margin
–
Return on equity, FY2025
–

Financial strength

Current ratio
0.60
Debt to equity
–
Debt to assets
–
Cash to current liabilities
19.7%

Valuation

P/E ratio
–
Price to sales
12.54
Price to book
–
Dividend yield
–

See a number that looks wrong?